Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The principal research objectives are to demonstrate cardioselective beta-blockade using
bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality
of life in patients with heart failure and coexistent moderate or severe chronic obstructive
pulmonary disease with or without significant reversibility. Patients will be followed up for
4 months during which bisoprolol will be up-titrated to the maximum clinically tolerated
dose. Health status will be assessed using a generic and two disease specific questionnaires,
and pulmonary function by spirometry, body box plethysmography, and cardiopulmonary exercise
testing.